Aardvark Therapeutics annual ebitda
2022
2023
2024
2025
Aardvark Therapeutics EBITDA Growth & History (AARD)
Aardvark Therapeutics's calculated EBITDA was −$62.7M for fiscal 2025.
View full Aardvark Therapeutics company overviewAardvark Therapeutics annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$62.7M | −$39.9M | — |
| 2024 | 2024-12-31 | −$22.8M | −$16.1M | — |
| 2023 | 2023-12-31 | −$6.7M | $4.1M | — |
| 2022 | 2022-12-31 | −$10.8M | — | — |
Aardvark Therapeutics quarterly ebitda
Q1.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$15.1M | $764,000 | — |
| Q1 2026 | 2026-03-31 | −$22.5M | −$12.0M | — |
| Q4 2025 | 2025-12-31 | −$18.7M | — | — |
| Q3 2025 | 2025-09-30 | −$17.7M | −$12.6M | — |
| Q2 2025 | 2025-06-30 | −$15.8M | — | — |
| Q1 2025 | 2025-03-31 | −$10.5M | −$8.3M | — |
| Q3 2024 | 2024-09-30 | −$5.1M | — | — |
| Q1 2024 | 2024-03-31 | −$2.2M | — | — |
Aardvark Therapeutics ebitda trends
Between the periods ended 2022-12-31 and 2025-12-31, Aardvark Therapeutics's ebitda decreased from −$10.8M to −$62.7M, a change of −$51.9M. The latest reported quarter, Q2 2026, shows −$15.1M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Aardvark Therapeutics source filings ↗Community posts
FDA lifts Aardvark's ARD-101 hold as further trial planning continues
Aardvark Therapeutics ($AARD) said the FDA lifted the clinical hold on ARD-101, its investigational treatment for excessive hunger associated with Prader-Willi syndrome. The hold followed a voluntary dosing pause after reversible electrocar ...
